T-Cell Activation Independently Associates with Immune Senescence in HIV-Infected Recipients of Long-term Antiretroviral Treatment

Journal of Infectious Diseases

Volumn 214, Issue 2, 2016, Pages 216-225

  Jimnez, Viviana Cobos ^a,c   Wit, Ferdinand W N M ^a,b,c   Joerink, Maaike ^a,c   Maurer, Irma ^a   Harskamp, Agnes M ^a   Schouten, Judith ^a,b,c   Prins, Maria ^e   Van Leeuwen, Ester M M ^a   Booiman, Thijs ^a,c   Deeks, Steven G ^f   Reiss, Peter ^a,b,c,d   Kootstra, Neeltje A ^a   Reiss, P ^a   Wit, F W N M ^a   Van Der Valk, M ^a   Schouten, J ^a   Kooij, K W ^a   Van Zoest, R A ^a   Elsenga, B C ^a   Prins, M ^a   Martens, M ^a   Moll, S ^a   Berkel, J ^a   Tott, M ^a   Visser, G R ^a   Kovalev, S ^a   Zaheri, S ^a   Hillebregt, M M J ^a   Ruijs, Y M C ^a   Benschop, D P ^a   Reis, P ^a   Janssen, F R ^a   Heidenrijk, M ^a   Zikkenheiner, W ^a   Boumans, L ^a   Harskamp Holwerda, A M ^a   Maurer, I ^a   Mangas Ruiz, M M ^a   Girigorie, A F ^a   Boeser Nunnink, B ^a   Geerlings, S E ^a   Godfried, M H ^a   Goorhuis, A ^a   Hovius, J W R ^a   Nellen, F J B ^a   Van Der Meer, J T M ^a   Van Der Poll, T ^a   Prins, J M ^a   Wiersinga, W J ^a   Van Eden, J ^a   Van Hes, A M H ^a   Mutschelknauss, M ^a   Nobel, H E ^a   Pijnappel, F J J ^a   Westerman, A M ^a   De Jong, J ^a   Postema, P G ^a   Bisschop, P H L T ^a   Serlie, M J M ^a   Lips, P ^a   Dekker, E ^a   De Rooij, S E J A ^a   Willemsen, J M R ^a   Vogt, L ^a   Portegies, P ^a   Schmand, B A ^a   Geurtsen, G J ^a   Ter Stege, J A ^a   Klein Twennaar, M ^a   Van Eck Smit, B L F ^a   De Jong, M ^a   Richel, D J ^a   Verbraak, F D ^a   Demirkaya, N ^a   Visser, I ^a   Ruh, H G ^a   Nieuwkerk, P T ^a   Van Steenwijk, R P ^a   DIjkers, E ^a   Majoie, C B L M ^a   Caan, M W A ^a   Su, T ^a   Van Lunsen, H W ^a   Nievaard, M A F ^a   Van Den Born, B J H ^a   Stroes, E S G ^a   Mulder, W M C ^a   more..

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b Department of Global Health ^*  (Netherlands)

^c AMSTERDAM INSTITUTE FOR GLOBAL HEALTH AND DEVELOPMENT   (Netherlands)

^d STICHTING HIV MONITORING   (Netherlands)

^e DEPARTMENT OF INFECTIOUS DISEASES   (Netherlands)

^f UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

ART; HIV; Immune activation; Senescence; Telomeres; Thymic output

Indexed keywords

ANTIVIRUS AGENT; CD14 ANTIGEN; CD27 ANTIGEN; CD28 ANTIGEN; CD31 ANTIGEN; CD38 ANTIGEN; CD57 ANTIGEN; CYTOMEGALOVIRUS ANTIBODY; HLA DR ANTIGEN; PROGRAMMED DEATH 1 RECEPTOR; T LYMPHOCYTE RECEPTOR; ANTIRETROVIRUS AGENT; PDCD1 PROTEIN, HUMAN;

ADULT; AGED; ANTIBODY TITER; ARTICLE; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOSENESCENCE; IMMUNOSTIMULATION; MAJOR CLINICAL STUDY; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TELOMERE; THYMUS; AGING; BLOOD; CHEMISTRY; COHORT ANALYSIS; HIV INFECTIONS; IMMUNOLOGY; IMMUNOPHENOTYPING; LYMPHOCYTE ACTIVATION; METABOLISM; MIDDLE AGED; T LYMPHOCYTE SUBPOPULATION;

AGED; AGING; ANTI-RETROVIRAL AGENTS; ANTIGENS, CD14; COHORT STUDIES; FEMALE; HIV INFECTIONS; HUMANS; IMMUNOPHENOTYPING; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; PROGRAMMED CELL DEATH 1 RECEPTOR; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, REGULATORY; TELOMERE; THYMUS GLAND;

EID: 84977080475     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiw146     Document Type: Article

References (49)

1. van Sighem AI, van de Wiel MA, Ghani AC, et al. Mortality and progression to AIDS after starting highly active antiretroviral therapy. AIDS 2003; 17:2227-36.
2. Wada N, Jacobson LP, Cohen M, French A, Phair J, Munoz A. Cause-specific life expectancies after 35 years of age for human immunodeficiency syndromeinfected and human immunodeficiency syndrome-negative individuals followed simultaneously in long-term cohort studies, 1984-2008. Am J Epidemiol 2013; 177:116-25.
3. Goulet JL, Fultz SL, Rimland D, et al. Aging and infectious diseases: do patterns of comorbidity vary by HIV status, age, and HIV severity? Clin Infect Dis 2007; 45:1593-601.
4. Guaraldi G, Orlando G, Zona S, et al. Premature age-related comorbidities among HIV-infected persons compared with the general population. Clin Infect Dis 2011; 53:1120-6.
5. Schouten J, Wit FW, Stolte IG, et al. Cross-sectional comparison of the prevalence of age-associated comorbidities and their risk factors between HIV-infected and uninfected individuals: the AGEhIV cohort study. Clin Infect Dis 2014; 59:1787-97.
6. Deeks SG. HIV infection, inflammation, immunosenescence, and aging. Annu Rev Med 2011; 62:141-55.
7. Deeks SG, Tracy R, Douek DC. Systemic effects of inflammation on health during chronic HIV infection. Immunity 2013; 39:633-45.
8. Singh T, Newman AB. Inflammatory markers in population studies of aging. Ageing Res Rev 2011; 10:319-29.
9. Appay V, Fastenackels S, Katlama C, et al. Old age and anti-cytomegalovirus immunity are associated with altered T-cell reconstitution in HIV-1-infected patients. AIDS 2011; 25:1813-22.
10. Naeger DM, Martin JN, Sinclair E, et al. Cytomegalovirus-specific T cells persist at very high levels during long-term antiretroviral treatment of HIV disease. PLoS One 2010; 5:e8886.
11. Dock JN, Effros RB. Role of CD8T cell replicative senescence in human aging and in HIV-mediated immunosenescence. Aging Dis 2011; 2:382-97.
12. Desai S, Landay A. Early immune senescence in HIV disease. Curr HIV/AIDS Rep 2010; 7:4-10.
13. Brenchley JM, Karandikar NJ, Betts MR, et al. Expression of CD57 defines replicative senescence and antigen-induced apoptotic death of CD8+ T cells. Blood 2003; 101:2711-20.
14. Lamoreaux L, Roederer M, Koup R. Intracellular cytokine optimization and standard operating procedure. Nat Protoc 2006; 1:1507-16.
15. Kern F, Faulhaber N, Frommel C, et al. Analysis of CD8T cell reactivity to cytomegalovirus using protein-spanning pools of overlapping pentadecapeptides. Eur J Immunol 2000; 30:1676-82.
16. Cawthon RM. Telomere length measurement by a novel monochrome multiplex quantitative PCR method. Nucleic Acids Res 2009; 37:e21.
17. Ferrando-Martinez S, Franco JM, Ruiz-Mateos E, et al. A reliable and simplified sj/beta-TREC ratio quantification method for human thymic output measurement. J Immunol Methods 2010; 352:111-7.
18. Harley CB, Futcher AB, Greider CW. Telomeres shorten during ageing of human fibroblasts. Nature 1990; 345:458-60.
19. Hodes RJ. The effects of aging on lymphocyte development and function: introduction. Springer Semin Immunopathol 2002; 24:1-5.
20. Papagno L, Spina CA, Marchant A, et al. Immune activation and CD8+ T-cell differentiation towards senescence in HIV-1 infection. PLoS Biol 2004; 2:E20.
21. Lee SA, Sinclair E, Hatano H, et al. Impact of HIV on CD8+ T cell CD57 expression is distinct from that of CMV and aging. PLoS One 2014; 9:e89444.
22. Lee SA, Sinclair E, Jain V, et al. Low proportions of CD28-CD8+ T cells expressing CD57 can be reversed by early ART initiation and predict mortality in treated HIV infection. J Infect Dis 2014; 210:374-82.
23. Raimondi G, Shufesky WJ, Tokita D, Morelli AE, Thomson AW. Regulated compartmentalization of programmed cell death-1 discriminates CD4+CD25+ resting regulatory T cells from activated T cells. J Immunol 2006; 176:2808-16.
24. Koch S, Larbi A, Ozcelik D, et al. Cytomegalovirus infection: a driving force in human T cell immunosenescence. Ann N Y Acad Sci 2007; 1114:23-35.
25. Hasse B, Ledergerber B, Furrer H, et al. Morbidity and aging in HIV-infected persons: the Swiss HIV cohort study. Clin Infect Dis 2011; 53:1130-9.
26. Kaufmann GR, Perrin L, Pantaleo G, et al. CD4 T-lymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years: the Swiss HIV Cohort Study. Arch Intern Med 2003; 163:2187-95.
27. Serrano-Villar S, Sainz T, Lee SA, et al. HIV-infected individuals with low CD4/ CD8 ratio despite effective antiretroviral therapy exhibit altered T cell subsets, heightened CD8+ T cell activation, and increased risk of non-AIDS morbidity and mortality. PLoS Pathog 2014; 10:e1004078.
28. Bucy RP, Hockett RD, Derdeyn CA, et al. Initial increase in blood CD4(+) lymphocytes after HIV antiretroviral therapy reflects redistribution from lymphoid tissues. J Clin Invest 1999; 103:1391-8.
29. Walker RE, Carter CS, Muul L, et al. Peripheral expansion of pre-existing mature T cells is an important means of CD4+ T-cell regeneration HIV-infected adults. Nat Med 1998; 4:852-6.
30. Douek DC, McFarland RD, Keiser PH, et al. Changes in thymic function with age and during the treatment of HIV infection. Nature 1998; 396:690-5.
31. Franco JM, Rubio A, Martinez-Moya M, et al. T-cell repopulation and thymic volume in HIV-1-infected adult patients after highly active antiretroviral therapy. Blood 2002; 99:3702-6.
32. Teixeira L, Valdez H, McCune JM, et al. Poor CD4T cell restoration after suppression of HIV-1 replication may reflect lower thymic function. AIDS 2001; 15:1749-56.
33. McCune JM, Loftus R, Schmidt DK, et al. High prevalence of thymic tissue in adults with human immunodeficiency virus-1 infection. J Clin Invest 1998; 101:2301-8.
34. Cockerham LR, Siliciano JD, Sinclair E, et al. CD4+ and CD8+ T cell activation are associated with HIV DNA in resting CD4+ T cells. PLoS One 2014; 9:e110731.
35. Chevalier MF, Petitjean G, Dunyach-Remy C, et al. The Th17/Treg ratio, IL-1RA and sCD14 levels in primary HIV infection predict the T-cell activation set point in the absence of systemic microbial translocation. PLoS Pathog 2013; 9:e1003453.
36. O'Donovan A, Pantell MS, Puterman E, et al. Cumulative inflammatory load is associated with short leukocyte telomere length in the Health, Aging and Body Composition Study. PLoS One 2011; 6:e19687.
37. Srinivasa S, Fitch KV, Petrow E, et al. Soluble CD163 is associated with shortened telomere length in HIV-infected patients. J Acquir Immune Defic Syndr 2014; 67:414-8.
38. Wong JY, De Vivo I, Lin X, Fang SC, Christiani DC. The relationship between inflammatory biomarkers and telomere length in an occupational prospective cohort study. PLoS One 2014; 9:e87348.
39. Vasto S, Colonna-Romano G, Larbi A, Wikby A, Caruso C, Pawelec G. Role of persistent CMV infection in configuring T cell immunity in the elderly. Immun Ageing 2007; 4:2.
40. Parrinello CM, Sinclair E, Landay AL, et al. Cytomegalovirus immunoglobulin G antibody is associated with subclinical carotid artery disease among HIV-infected women. J Infect Dis 2012; 205:1788-96.
41. Brunt SJ, Lee S, D'Orsogna L, Bundell C, Burrows S, Price P. The use of humoral responses as a marker of CMV burden in HIV patients on ART requires consideration of T-cell recovery and persistent B-cell activation. Dis Markers 2014; 2014:947432.
42. Belkaid Y. Regulatory T cells and infection: a dangerous necessity. Nat Rev Immunol 2007; 7:875-88.
43. Shevach EM. Mechanisms of foxp3+ T regulatory cell-mediated suppression. Immunity 2009; 30:636-45.
44. Lim A, Tan D, Price P, et al. Proportions of circulating T cells with a regulatory cell phenotype increase with HIV-associated immune activation and remain high on antiretroviral therapy. AIDS 2007; 21:1525-34.
45. Piconi S, Trabattoni D, Gori A, et al. Immune activation, apoptosis, and Treg activity are associated with persistently reduced CD4+ T-cell counts during antiretroviral therapy. AIDS 2010; 24:1991-2000.
46. Weiss L, Piketty C, Assoumou L, et al. Relationship between regulatory T cells and immune activation in human immunodeficiency virus-infected patients interrupting antiretroviral therapy. PLoS One 2010; 5:e11659.
47. Kwon DS, Angin M, Hongo T, et al. CD4+ CD25+ regulatory T cells impair HIV-1-specific CD4T cell responses by upregulating interleukin-10 production in monocytes. J Virol 2012; 86:6586-94.
48. Said EA, Dupuy FP, Trautmann L, et al. Programmed death-1-induced interleukin-10 production by monocytes impairs CD4+ T cell activation during HIV infection. Nat Med 2010; 16:452-9.
49. Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity 2013; 39:1-10.